Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3
Fuente:
FierceBiotech
Two of Kodiak Sciences’ drug candidates have matched aflibercept in a phase 3 clinical trial, positioning the biotech to seek FDA approval of one of the eye disease assets this year.